Evercore ISI lowered the firm’s price target on Viridian Therapeutics (VRDN) to $24 from $32 and keeps an Outperform rating on the shares in conjunction with a Q1 earnings preview.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRDN:
- Viridian Therapeutics price target lowered to $36 from $40 at Truist
- Viridian Therapeutics price target lowered to $31 from $37 at Wedbush
- 3 Best Trending Stocks, According to Analysts – 4/7/2026
- Viridian Therapeutics price target lowered to $30 from $42 at RBC Capital
- Viridian Therapeutics removed from Best Ideas List at Wedbush